166 related articles for article (PubMed ID: 38332640)
21. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
22. Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis.
Ipek Y; Kilic B; Gunay UB; Eskazan AE
Expert Opin Investig Drugs; 2023; 32(10):931-940. PubMed ID: 37811861
[TBL] [Abstract][Full Text] [Related]
23. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
24. Novel treatments for myelofibrosis: beyond JAK inhibitors.
Tremblay D; Mesa R
Int J Hematol; 2022 May; 115(5):645-658. PubMed ID: 35182376
[TBL] [Abstract][Full Text] [Related]
25. FDA approves fourth JAK inhibitor for myelofibrosis.
Mullard A
Nat Rev Drug Discov; 2023 Nov; 22(11):862. PubMed ID: 37803081
[No Abstract] [Full Text] [Related]
26. Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Koschmieder S; Isfort S; Schulte C; Jacobasch L; Geer T; Reiser M; Koenigsmann M; Heinrich B; Wehmeyer J; von der Heyde E; Tesch H; Gröschl B; Bachhuber P; Großer S; Pahl HL
Ann Hematol; 2023 Dec; 102(12):3383-3399. PubMed ID: 37792065
[TBL] [Abstract][Full Text] [Related]
27. Comparison of clinical outcomes between transplant and nontransplant therapies in myelofibrosis following failure of first-line JAK-inhibitor.
England JT; Atenafu EG; Kennedy JA; Goraya B; Cheung V; Nye T; Gauthier K; Davidson MB; Bankar A; Sibai H; Maze D; Viswabandya A; Gupta V
Am J Hematol; 2023 May; 98(5):E127-E129. PubMed ID: 36814403
[No Abstract] [Full Text] [Related]
28. Anemia in myelofibrosis: Current and emerging treatment options.
Passamonti F; Harrison CN; Mesa RA; Kiladjian JJ; Vannucchi AM; Verstovsek S
Crit Rev Oncol Hematol; 2022 Dec; 180():103862. PubMed ID: 36332787
[TBL] [Abstract][Full Text] [Related]
29. An evaluation of fedratinib for adult patients with newly diagnosed and previously treated myelofibrosis.
Saleh K; Ribrag V
Expert Rev Hematol; 2023 Apr; 16(4):227-236. PubMed ID: 36939633
[TBL] [Abstract][Full Text] [Related]
30. Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A; Tefferi A
Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025
[TBL] [Abstract][Full Text] [Related]
31. Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Kosiorek HE; Scherber RM; Geyer HL; Verstovsek S; Langlais BT; Mazza GL; Gotlib J; Gupta V; Padrnos LJ; Palmer JM; Fleischman A; Mesa RA; Dueck AC
Br J Haematol; 2022 Sep; 198(6):1065-1068. PubMed ID: 35751150
[No Abstract] [Full Text] [Related]
32. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
33. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
34. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
[TBL] [Abstract][Full Text] [Related]
36. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger M; Miller C; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner E; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Koumenis IL; Sun W; Sandor V; Kantarjian HM
N Engl J Med; 2012 Mar; 366(9):799-807. PubMed ID: 22375971
[TBL] [Abstract][Full Text] [Related]
37. The safety of JAK kinase inhibitors for the treatment of myelofibrosis.
Coltro G; Vannucchi AM
Expert Opin Drug Saf; 2021 Feb; 20(2):139-154. PubMed ID: 33327810
[TBL] [Abstract][Full Text] [Related]
38. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
Koschmieder S; Jost E; Cornelissen C; Müller T; Schulze-Hagen M; Bickenbach J; Marx G; Kleines M; Marx N; Brümmendorf TH; Dreher M
Eur J Haematol; 2020 Nov; 105(5):655-658. PubMed ID: 32593209
[TBL] [Abstract][Full Text] [Related]
39. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
